Evaluation of Respiratory Muscle Sarcopenia in Obstructive Sleep Apnea Syndrome
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Anthropometric measurement
研究概览
简要总结
OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients.
This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.
详细描述
In the study, respiratory muscle sarcopenia will be evaluated in OSAS patients. It will be evaluated whether the expiratory pressure value, peek flow meter value and 6-minute walking distance are predictors of respiratory sarcopenia for OSAS.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with normal-mild-medium-severe OSAS
- •18 years and above
- •Turkish speaking patients will be included.
排除标准
- •Pregnancy,
- •Latent autoimmune diabetes,
- •Chronic renal failure,
- •Active or serious infections,
- •Liver failure,
- •Recent major cardiovascular events,
- •Unstable angina, heart failure (NYHA III-IV),
- •Patients with neurological or musculoskeletal disorders that create limitations in walking and performing tests
结局指标
主要结局
Anthropometric measurement
时间窗: 1 year
Waist circumference, hip circumference will be measured, waist-hip ratio will be calculated.
BOdy mass measurement
时间窗: 1 year
Body weight,fat-free mass (FFM) and appendicular skeletal muscle mass (ASMM) and skeletal muscle mass expressed in kilograms will be measured by bioelectrical impedance.
Hand Grip strength
时间窗: 1 year
Jamar hand dynamometer, which is recommended by the American Association of Hand Therapists (AETD) and has been found to have high validity and reliability in many studies and is therefore considered the gold standard, will be used to measure hand grip strength.
Walking speed
时间窗: 1 year
Walking speed will be measured with the 4 Meter Walking Speed Test (4MYHT).
Respiratory muscle strength:
时间窗: 1 year
Respiratory muscle strength will be evaluated with a portable, electronic mouth pressure measurement device.
Expiratory flow rate
时间窗: 1 year
Peak expiratory flow (PEF), also called peak expiratory flow rate (PEFR) and peak flow measurement, will be measured with a PEFmeter (MSA 100 PEFmeter), a small, hand-held device used to monitor a person's ability to breathe air.
Respiratory function test
时间窗: 1 year
To evaluate pulmonary functions(FEV1/FVC ve FEV1 ), it will be measured in a sitting position with a Spirolab III brand spirometer according to ATS/European Respiratory Society (ERS) criteria.
次要结局
- Functional capacity(1 year)
研究者
Nurel Ertürk
Assist. Prof. PT. PhD Nurel Ertürk
Tarsus University